Diagnostic Medical Systems SA
Diagnostic Medical Systems S.A. engages in the design, development, manufacture, and sale of medical imaging systems in France. It offers ADAM, in-house software suite; R and F solutions; bone densitometry; chest and bone room; mobile; c-arm; retrofit kit; and mammography equipment. The company was founded in 1979 and is headquartered in Gallargues-le-Montueux, France.
Diagnostic Medical Systems SA (ALDMS) - Net Assets
Latest net assets as of June 2025: €12.52 Million EUR
Based on the latest financial reports, Diagnostic Medical Systems SA (ALDMS) has net assets worth €12.52 Million EUR as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€57.17 Million) and total liabilities (€44.64 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €12.52 Million |
| % of Total Assets | 21.91% |
| Annual Growth Rate | 1.23% |
| 5-Year Change | -16.93% |
| 10-Year Change | -43.97% |
| Growth Volatility | 26.21 |
Diagnostic Medical Systems SA - Net Assets Trend (2009–2024)
This chart illustrates how Diagnostic Medical Systems SA's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Diagnostic Medical Systems SA (2009–2024)
The table below shows the annual net assets of Diagnostic Medical Systems SA from 2009 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €14.16 Million | +3.20% |
| 2023-12-31 | €13.72 Million | -24.47% |
| 2022-12-31 | €18.17 Million | -11.10% |
| 2021-12-31 | €20.44 Million | +19.89% |
| 2020-12-31 | €17.05 Million | +14.86% |
| 2019-12-31 | €14.84 Million | -16.99% |
| 2018-12-31 | €17.88 Million | -23.42% |
| 2017-12-31 | €23.35 Million | -17.42% |
| 2016-12-31 | €28.27 Million | +11.87% |
| 2015-12-31 | €25.27 Million | +14.84% |
| 2014-12-31 | €22.01 Million | +63.37% |
| 2013-12-31 | €13.47 Million | -3.66% |
| 2012-12-31 | €13.98 Million | +57.02% |
| 2011-12-31 | €8.90 Million | -20.25% |
| 2010-12-31 | €11.17 Million | -5.24% |
| 2009-12-31 | €11.78 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Diagnostic Medical Systems SA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 315200000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | €24.70 Million | 192.43% |
| Other Comprehensive Income | €-11.33 Million | -88.24% |
| Other Components | €2.34 Million | 18.25% |
| Total Equity | €12.84 Million | 100.00% |
Diagnostic Medical Systems SA Competitors by Market Cap
The table below lists competitors of Diagnostic Medical Systems SA ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Iep Invest
BR:IEP
|
$13.39 Million |
|
Brainzcompany Co. Ltd.
KQ:099390
|
$13.39 Million |
|
Sprint Bioscience AB
ST:SPRINT
|
$13.41 Million |
|
Global Consumer Public Company Limited
BK:GLOCON
|
$13.41 Million |
|
Lulu's Fashion Lounge Holdings Inc
NASDAQ:LVLU
|
$13.39 Million |
|
Econframe Bhd
KLSE:0227
|
$13.39 Million |
|
Innodep Inc.
KQ:303530
|
$13.38 Million |
|
UFO Moviez India Limited
NSE:UFO
|
$13.38 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Diagnostic Medical Systems SA's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 12,383,000 to 12,836,000, a change of 453,000 (3.7%).
- Net loss of 2,880,000 reduced equity.
- Share repurchases of 11,000 reduced equity.
- New share issuances of 11,000 increased equity.
- Other comprehensive income decreased equity by 488,000.
- Other factors increased equity by 3,821,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-2.88 Million | -22.44% |
| Share Repurchases | €11.00K | -0.09% |
| Share Issuances | €11.00K | +0.09% |
| Other Comprehensive Income | €-488.00K | -3.8% |
| Other Changes | €3.82 Million | +29.77% |
| Total Change | €- | 3.66% |
Book Value vs Market Value Analysis
This analysis compares Diagnostic Medical Systems SA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.78x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.31x to 1.78x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2009-12-31 | €4.12 | €1.26 | x |
| 2010-12-31 | €3.52 | €1.26 | x |
| 2011-12-31 | €1.89 | €1.26 | x |
| 2012-12-31 | €2.15 | €1.26 | x |
| 2013-12-31 | €1.60 | €1.26 | x |
| 2014-12-31 | €2.56 | €1.26 | x |
| 2015-12-31 | €1.30 | €1.26 | x |
| 2016-12-31 | €1.60 | €1.26 | x |
| 2017-12-31 | €1.48 | €1.26 | x |
| 2018-12-31 | €1.12 | €1.26 | x |
| 2019-12-31 | €0.91 | €1.26 | x |
| 2020-12-31 | €1.06 | €1.26 | x |
| 2021-12-31 | €1.16 | €1.26 | x |
| 2022-12-31 | €0.97 | €1.26 | x |
| 2023-12-31 | €0.71 | €1.26 | x |
| 2024-12-31 | €0.71 | €1.26 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Diagnostic Medical Systems SA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -22.44%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -6.25%
- • Asset Turnover: 0.85x
- • Equity Multiplier: 4.20x
- Recent ROE (-22.44%) is above the historical average (-23.24%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2009 | -51.88% | -38.75% | 0.79x | 1.70x | €-7.24 Million |
| 2010 | -52.85% | -32.04% | 0.84x | 1.96x | €-6.95 Million |
| 2011 | -26.62% | -11.01% | 1.01x | 2.39x | €-3.22 Million |
| 2012 | 1.86% | 0.92% | 1.21x | 1.67x | €-1.13 Million |
| 2013 | -7.26% | -4.36% | 0.94x | 1.76x | €-2.31 Million |
| 2014 | -5.37% | -4.45% | 0.63x | 1.93x | €-3.14 Million |
| 2015 | -11.04% | -7.37% | 0.78x | 1.91x | €-5.11 Million |
| 2016 | -5.43% | -3.60% | 0.75x | 2.02x | €-3.82 Million |
| 2017 | -3.62% | -3.13% | 0.68x | 1.71x | €-3.20 Million |
| 2018 | -30.21% | -22.42% | 0.66x | 2.04x | €-7.26 Million |
| 2019 | -22.09% | -10.44% | 0.77x | 2.75x | €-4.70 Million |
| 2020 | -30.78% | -16.28% | 0.70x | 2.69x | €-6.94 Million |
| 2021 | -20.69% | -10.68% | 0.68x | 2.83x | €-5.75 Million |
| 2022 | -43.55% | -19.34% | 0.65x | 3.44x | €-8.39 Million |
| 2023 | -39.94% | -11.21% | 0.86x | 4.13x | €-6.18 Million |
| 2024 | -22.44% | -6.25% | 0.85x | 4.20x | €-4.16 Million |
Industry Comparison
This section compares Diagnostic Medical Systems SA's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $35,648,323
- Average return on equity (ROE) among peers: -32.80%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Diagnostic Medical Systems SA (ALDMS) | €12.52 Million | -51.88% | 3.56x | $13.39 Million |
| Affluent Medical SAS (AFME) | $33.83 Million | -45.01% | 0.77x | $31.64 Million |
| Biosynex (ALBIO) | $124.31 Million | -29.72% | 0.94x | $7.06 Million |
| Bluelinea SA (ALBLU) | $1.96 Million | -41.72% | 0.71x | $6.02 Million |
| Carmat (ALCAR) | $-43.76 Million | 0.00% | 0.00x | $3.28 Million |
| Eurobio Scientific SA (ALERS) | $175.17 Million | 2.76% | 0.81x | $5.52 Million |
| Ikonisys SA (ALIKO) | $20.01 Million | -2.85% | 0.13x | $9.76 Million |
| Implanet SA (ALIMP) | $3.54 Million | -99.97% | 3.09x | $6.96 Million |
| Mediantechn (ALMDT) | $0.00 | 0.00% | 0.00x | $86.92 Million |
| Spineguard (ALSGD) | $5.77 Million | -78.70% | 0.48x | $5.70 Million |